Thanks Bunda! Some nice new details on IMP761 here. 18months...

Thanks Bunda! Some nice new details on IMP761 here. 18months isn't long, so news flow will start ramping soonish on this potential blockbuster which should be closely watched by investors because a developing unique platform in autoimmune will attract a new set of investors familiar with this space. Just the de-risking alone will significantly boost the share price. Two blockbuster lag3 platforms in totally different diseases with massive universal potential and unfathomable market potential... Triebel is a genius.

_"Then, we use LAG-3 as a functional receptor to increase negative signaling into these autoimmune T cells through a unique LAG-3 cross-linking mechanism with an agonist anti-LAG-3 antibody, IMP761. These self-reactive T cells, which are the root cause of autoimmunity, are then silenced.” From a purely medical point of view, Triebel said this approach would seem to be more beneficial than general immunosuppressants like corticosteroids, methotrexate (often used to treat rheumatoid arthritis), or blockers of inflammation mediators. The challenge, he said, is, “you have to find the right epitope on LAG-3, organized by antibody, to make it work."
According to Immutep, IMP761, an agonist antibody, is the only one of its kind currently in development. It is presently being studied at the preclinical stage and Immutep anticipates being in the clinic in approximately 18 months."

There's a lot going on in 18months.. ph3 AIPAC trial started, maturing data from our Keytruda and Insight trials and IMP761 starting. Immutep will need a lot more cash... Anyone got any ideas how this is all going to play out?